Results of Annual General Meeting

RNS Number : 7232G

e-Therapeutics plc

31 May 2017

 

e-Therapeutics plc

('e-Therapeutics' or the 'Company')

Results of Annual General Meeting

Oxford, UK, 31 May 2017 - e-Therapeutics plc (AIM: ETX) is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 8 May 2017 were duly passed by shareholders of the Company at the Annual General Meeting held earlier today.

-Ends-

Contacts:

e-Therapeutics plc Ray Barlow, CEO Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Alex Shaw	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform.  The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.  The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

 

END

 

 

RAGUARORBRAVOAR